Who are Spiromax Budesonide/formoterol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Salmeterol 50 mcg via DISKUS, Symbicort Turbuhaler, levalbuterol tartrate MDI, Salmeterol/Fluticasone propionate combination product, Placebo to Salmeterol/fluticasone, long-acting beta2-agonist.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spiromax-budesonide-formoterol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Spiromax Budesonide/formoterol — Competitive Intelligence Brief

Spiromax Budesonide/formoterol (Spiromax Budesonide/formoterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid/long-acting beta2-adrenergic receptor agonist. Area: Respiratory.

phase 3 Corticosteroid/long-acting beta2-adrenergic receptor agonist Beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Spiromax Budesonide/formoterol (Spiromax Budesonide/formoterol) — University Medical Center Groningen. Spiromax Budesonide/formoterol is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist used to treat asthma and COPD.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Spiromax Budesonide/formoterol TARGET	Spiromax Budesonide/formoterol	University Medical Center Groningen	phase 3	Corticosteroid/long-acting beta2-adrenergic receptor agonist	Beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS	Salmeterol 50 mcg via DISKUS	GlaxoSmithKline	marketed	Long-acting beta2-adrenergic agonist (LABA)	Beta2-adrenergic receptors
Symbicort Turbuhaler	Symbicort Turbuhaler	Orion Corporation, Orion Pharma	phase 3	Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination	Beta2-adrenergic receptor
levalbuterol tartrate MDI	levalbuterol tartrate MDI	Sumitomo Pharma America, Inc.	phase 3	Long-acting beta2-adrenergic receptor agonist	beta2-adrenergic receptor
Salmeterol/Fluticasone propionate combination product	Salmeterol/Fluticasone propionate combination product	GlaxoSmithKline	phase 3	Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination	Beta2-adrenergic receptor
Placebo to Salmeterol/fluticasone	Placebo to Salmeterol/fluticasone	Novartis	phase 3	Long-acting beta2-adrenergic receptor agonist and corticosteroid	Beta2-adrenergic receptor and glucocorticoid receptor
long-acting beta2-agonist	long-acting beta2-agonist	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Long-acting beta2-agonist (LABA)	Beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid/long-acting beta2-adrenergic receptor agonist class)

University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Spiromax Budesonide/formoterol — Competitive Intelligence Brief. https://druglandscape.com/ci/spiromax-budesonide-formoterol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab